The predictive value of anti-SS-A antibodies titration in pregnant women with fetal congenital heart block

REFERENCES

• Salomonsson S, Strandberg L. Autoantibodies associated with congenital heart block. Scand Immunol. 2010;72:185–8.
   PubMed Web of Science ®Google Scholar
• Copel J, Buyon J, Kleinman C. Successful in utero therapy of fetal heart block. Am J Obstet Gynecol. 1995;173:1384–90.
   Google Scholar
• Buyon J, Waltuck J, Kleinman C, Copel J. In utero identification and therapy of congenital heart block. Lupus. 1995;4:116–21.
   PubMed Web of Science ®Google Scholar
• Buyon J, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: demo-graphics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31:1658–66.
   PubMed Web of Science ®Google Scholar
• Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SS-A antibodies detected by counter-immunoelectrophoresis: a prospective study of 100 women. Arthr Rheum. 2001;44 :1832–5.
   PubMed Web of Science ®Google Scholar
• Friedman D, Kim M, Copel J, Davis C, Phoon C, Glickstein J, et al. PRIDE investigators. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR interval and dexamethasone evaluation (PRIDE) prospective study. Circula-tion. 2008;29:485–93.
   Google Scholar
• Jaeggi E, Silverman E, Laskin C, Kingdom J, Golding F, Weber R. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SS-A and anti-La/SSB antibodies did not predict progressive heart block. A prospective observa-tional study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol. 2011;57:1487–92.
   Google Scholar
• Jaeggi E, Laskin C, Hamilton R, Kingdom J, Silverman E. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol. 2010;55: 2778–84.
   Google Scholar
• Brucato A, Astori M, Cimaz R, Villa P, Li Destri M, Chimini L, et al. Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero. Ann Rheum Dis. 2006;65 :1422–6.
   PubMed Web of Science ®Google Scholar
• Solomon D, Rupel A, Buyon J. Birth order, gender and recur-rence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus. 2003;12:646–7.
   Google Scholar
• Shinozuka N. Fetal biometry and fetal weight estimation: JSUM standardization. Ultrasound Rev Obset Gynecol. 2002;2:156–61.
   Google Scholar
• Shinozuka N, Akamatsu N, Sato S, Kanzaki T, Takeuchi H, Natori M, et al. Ellipse tracing fetal growth assessment using abdominal circumference JSUM standardization committee for fetal measurements. J Med Ultrasound. 2000;8:87–94.
   Google Scholar
• Jaeggi E, Silverman E, Yoo S, Kingdom J. Is immune-mediated complete fetal atrioventricular block reversible by transplacental dexamethasone therapy? Ultrasound Obstet Gynecol. 2004;23:602-5.
   Google Scholar
• Murakami A, Kojima K, Ohya K, Imamura K, Takasaki Y. A new conformational epitope generated by the binding of recom-binant 70-kd protein and Ul RNA to anti-U1 RNP autoantibodies in sera from patients with mixed connective tissue disease. Arthr Rheum. 2002;46: 3273–82.
   Google Scholar
• Tan E, Smolen J, McDougal J, Butcher B, Conn D, Dawkins R, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. Arthr Rheum. 1999;42:455–64.
   PubMed Web of Science ®Google Scholar
• Wahren-Herlenius M. Specificity and effector mechanisms of autoantibodies in congenital heart block. Curr Opin Immunol. 2006;18:690–6.
   PubMed Web of Science ®Google Scholar
• Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treat-ment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthr Rheum. 1999;42:2335–45.
   PubMedGoogle Scholar
• Newnham J, Moss T. Antenatal glucocorticoids and growth: single versus multiple doses in animal and human studies. Semin Neonatol. 2001;6:285–92.
   PubMedGoogle Scholar
• Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W Fl mice. J Exp Med. 1994;179:305–10.
   PubMed Web of Science ®Google Scholar
• Okamoto T. NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006;6:359–72.
   PubMedGoogle Scholar
• Buyon J, Clancy R, Friedman D. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, inte-grating clues from the bench and bedside. Nat Clin Pract Rheu-matol. 2009;5:139–48.
   Google Scholar
• Friedman D, Kim M, Copel J, Llanos C, Davis C, Buyon J. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and dexa-methasone evaluation (PRIDE) study. Am J Cardiol. 2009;103:1102–6.
   PubMed Web of Science ®Google Scholar
• Thomas T, Stefan L, Rosemarie M, Marvin M, Harry R. Detection of anti-Ro (SS-A) antibodies by gel double diffusion and a 'sand-wich' ELISA in systemic and subacute cutaneous lupus erythe-matosus and Sjögren's syndrome. J Autoimmun. 1991;4:87–96.
   Google Scholar
• Huffer D. The benefits of transplacental treatment of isolated con-genital complete heart block associated with maternal anti-Ro/SS-A antibodies: a review. Scand J Immunol. 2010;72:235–41.
   PubMed Web of Science ®Google Scholar
• Cederqvist L. Fetal immuno-globulin synthesis following maternal immune-suppression. Am J Obstet Gynecol. 1977;129: 687–90.
   PubMed Web of Science ®Google Scholar